Novo Nordisk on Friday appointed Mars CEO Poul Weihrauch as a board observer, aiming to strengthen its obesity drug strategy, expand direct-to-consumer sales, and position him for a full board nomination in 2027.
The Danish pharmaceutical company announced during its annual general meeting, highlighting a strategic shift as competition intensifies in the fast-growing weight-loss drug market.
Chairman Lars Rebien Sorensen says the appointment brings valuable consumer-focused expertise to the company. “Understanding how patients make decisions is increasingly important as healthcare becomes more consumer-driven,” he says.
Appointment Signals Push to Strengthen Obesity Market Strategy
Weihrauch, who leads global confectionery and pet care company Mars, joins as a board observer, a non-voting role that allows participation in discussions and strategic planning.
Novo Nordisk says it plans to nominate him as a full board member in 2027, underscoring a long-term effort to integrate consumer insights into its pharmaceutical business.
The move comes as the company seeks to maintain leadership in the obesity drug market, where demand for treatments continues to surge globally.
Analysts note that bringing in an executive with deep experience in consumer behavior could help Novo Nordisk better position its products in an increasingly competitive landscape.
Company Expands Direct Sales of Key GLP-1 Drugs
Novo Nordisk is also shifting how it reaches patients by offering its GLP-1 drugs, Wegovy and Ozempic, directly to consumers through its NovoCare Pharmacy and the TrumpRx website.
The approach reflects a broader trend in the pharmaceutical industry toward direct engagement with patients, bypassing traditional distribution channels.
Sorensen says the company is studying consumer behavior to refine its strategy. “We are examining how patients access treatment and what influences their choices,” he says.
The company aims to use these insights to improve accessibility and tailor its offerings to patient needs, particularly in the United States, its largest market.
Dividend, Buyback Plans Reflect Confidence in Growth
Novo Nordisk’s board also proposes a final dividend of 7.95 Danish kroner per share for 2025, signaling continued returns to shareholders.
In addition, the company launches a 15 billion kroner share buyback program, a move often seen as a sign of confidence in future earnings.
The financial decisions come despite mixed analyst sentiment, with some warning of potential pressure on the company’s weight-loss drug performance in the U.S. market.
Still, Novo Nordisk maintains that its long-term outlook remains strong, driven by sustained demand for obesity and diabetes treatments.
The company operates in more than 180 countries and continues to invest in expanding its portfolio across diabetes care, obesity treatments, and biopharmaceuticals.
Visit Healthcare 360 Magazine For The Most Recent Information.
